EQT Life Sciences Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 26
- Investments
- 204
- Portfolio
- 50
- Exits
- 92
EQT Life Sciences General Information
Description
Founded in 1988, Life Sciences Partners is a venture capital firm based in Amsterdam, Netherlands. The firm seeks to invest in the pharmaceuticals, biotechnology, and life sciences sectors in the United States and Western Europe.
Contact Information
Website
www.lspvc.com
Formerly Known As
Life Sciences Partners BV, LSP, LSP Management Group B.V., Life Sciences Partners
Year Founded
1998
Investor Status
Actively Seeking New Investments
Trade Association
Principles for Responsible Investment (PRI)
Primary Investor Type
Venture Capital
Other Investor Types
Accelerator/Incubator
Impact Investing
Primary Office
- Johannes Vermeerplein 9
- 1071 DV Amsterdam
- Netherlands
+31 020 000 0000
EQT Life Sciences Investments (204)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Perfuze | 09-Feb-2022 | Early Stage VC | 000.00 | Surgical Devices | Clinical Trials - General | 0000 00000000 00.0 |
| 0000 (00000000 000 | 28-Jan-2022 | 00000 00000 | 000.00 | Home Furnishings | Generating Revenue | 0000 00000000 00.0 |
| 0000000 (000000000 | 16-Dec-2021 | 00000 00000 | 000.00 | Therapeutic Devices | Generating Revenue | 0000 00000000 00.0 |
| 000000000 | 02-Dec-2021 | 00000 00000 | 00000 | Drug Discovery | Startup | 000000 000000000 |
| 0000000 0000000000 | 16-Nov-2021 | 00000 00000 | 00000 | Drug Discovery | Generating Revenue | 00000 00000 00.0 |
| 000 000000 | 26-Oct-2021 | 00000 00000 | 00000 | Biotechnology | Generating Revenue | 0000000 00000 00.0 |
| 0000 000000000000 | 22-Oct-2021 | 00000 00000 | 000.00 | Drug Discovery | Startup | 000000 0000000-000 000000 |
| 00000000000 | 14-Oct-2021 | 00000 00000 | 000.00 | Surgical Devices | Product Development | 0000 000000 00.0 |
| Amolyt Pharma | 16-Sep-2021 | Later Stage VC | 000.00 | Drug Discovery | Pre-Clinical Trials | 000000 0000000-000 000000 |
| Evommune | 09-Sep-2021 | Early Stage VC | 0000 | Drug Discovery | Pre-Clinical Trials |
EQT Life Sciences Exits (92)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| ONWARD (Therapeutic Devices) | 21-Oct-2021 | IPO | 000.00 |
| 000000 000000 | 16-Apr-2021 | 000000000000000000 | 00000 |
| 00000000 0000000 0 | 16-Mar-2021 | 000 | 00000 |
| 0000000 0000000000 | 04-Mar-2021 | 000 00 00000000 | |
| 0000 000000000 | 01-Mar-2021 | 000000000 00000000 | |
| 00000000 0000000 | 24-Feb-2021 | 000000000000000000 | 00000 |
| 000000000 | 05-Feb-2021 | 000 | 00000 |
| 0000000 0000000000 | 02-Feb-2021 | 000000000000000000 | 00000 |
| Nkarta Therapeutics | 13-Jul-2020 | IPO | 00000 |
| IlluminOss | 01-May-2020 | Buyout/LBO |
EQT Life Sciences Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialEQT Life Sciences Team (28)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Merijn Klaassen | Chief Financial Officer & Partner | Amsterdam, Netherlands | |||
| Martijn Kleijwegt | Founder & Managing Partner | 00 | 0 | 0 | Amsterdam, Netherlands |
| Joachim Rothe Ph.D | Managing Partner | 00 | 0 | 0 | Amsterdam, Netherlands |
| Mark Wegter | Managing Partner | 0 | 0 | 0 | Amsterdam, Netherlands |
| René Kuijten Ph.D | Managing Partner | 00 | 0 | 0 | Amsterdam, Netherlands |
EQT Life Sciences Co-Investors (198)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| Andera Partners | 7 | 0 | 0 |
|
|
| Kurma Partners | 0 | 0 |
|
|
|
| Idinvest Partners | 0 | 0 |
|
|
|
| Inkef Capital | 0 | 0 | 0 |
|
|
| Sofinnova Partners | 0 | 0 |
|
|